944 related articles for article (PubMed ID: 30554783)
1. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial.
Sanyal A; Charles ED; Neuschwander-Tetri BA; Loomba R; Harrison SA; Abdelmalek MF; Lawitz EJ; Halegoua-DeMarzio D; Kundu S; Noviello S; Luo Y; Christian R
Lancet; 2019 Dec; 392(10165):2705-2717. PubMed ID: 30554783
[TBL] [Abstract][Full Text] [Related]
2. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Harrison SA; Rinella ME; Abdelmalek MF; Trotter JF; Paredes AH; Arnold HL; Kugelmas M; Bashir MR; Jaros MJ; Ling L; Rossi SJ; DePaoli AM; Loomba R
Lancet; 2018 Mar; 391(10126):1174-1185. PubMed ID: 29519502
[TBL] [Abstract][Full Text] [Related]
3. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
Loomba R; Morgan E; Watts L; Xia S; Hannan LA; Geary RS; Baker BF; Bhanot S
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):829-838. PubMed ID: 32553151
[TBL] [Abstract][Full Text] [Related]
4. Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study.
Loomba R; Lawitz EJ; Frias JP; Ortiz-Lasanta G; Johansson L; Franey BB; Morrow L; Rosenstock M; Hartsfield CL; Chen CY; Tseng L; Charlton RW; Mansbach H; Margalit M
Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):120-132. PubMed ID: 36521501
[TBL] [Abstract][Full Text] [Related]
5. Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study.
Charles ED; Neuschwander-Tetri BA; Pablo Frias J; Kundu S; Luo Y; Tirucherai GS; Christian R
Obesity (Silver Spring); 2019 Jan; 27(1):41-49. PubMed ID: 30520566
[TBL] [Abstract][Full Text] [Related]
6. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
Armstrong MJ; Gaunt P; Aithal GP; Barton D; Hull D; Parker R; Hazlehurst JM; Guo K; ; Abouda G; Aldersley MA; Stocken D; Gough SC; Tomlinson JW; Brown RM; Hübscher SG; Newsome PN
Lancet; 2016 Feb; 387(10019):679-690. PubMed ID: 26608256
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.
Harrison SA; Frias JP; Neff G; Abrams GA; Lucas KJ; Sanchez W; Gogia S; Sheikh MY; Behling C; Bedossa P; Shao L; Chan D; Fong E; de Temple B; Shringarpure R; Tillman EJ; Rolph T; Cheng A; Yale K;
Lancet Gastroenterol Hepatol; 2023 Dec; 8(12):1080-1093. PubMed ID: 37802088
[TBL] [Abstract][Full Text] [Related]
8. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study.
Loomba R; Sanyal AJ; Nakajima A; Neuschwander-Tetri BA; Goodman ZD; Harrison SA; Lawitz EJ; Gunn N; Imajo K; Ravendhran N; Akahane T; Boone B; Yamaguchi M; Chatterjee A; Tirucherai GS; Shevell DE; Du S; Charles ED; Abdelmalek MF
Clin Gastroenterol Hepatol; 2024 Jan; 22(1):102-112.e9. PubMed ID: 37088457
[TBL] [Abstract][Full Text] [Related]
9. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Harrison SA; Bashir MR; Guy CD; Zhou R; Moylan CA; Frias JP; Alkhouri N; Bansal MB; Baum S; Neuschwander-Tetri BA; Taub R; Moussa SE
Lancet; 2019 Nov; 394(10213):2012-2024. PubMed ID: 31727409
[TBL] [Abstract][Full Text] [Related]
10. Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.
Harrison SA; Abdelmalek MF; Neff G; Gunn N; Guy CD; Alkhouri N; Bashir MR; Freilich B; Kohli A; Khazanchi A; Sheikh MY; Leibowitz M; Rinella ME; Siddiqui MS; Kipnes M; Moussa SE; Younes ZH; Bansal M; Baum SJ; Borg B; Ruane PJ; Thuluvath PJ; Gottwald M; Khan M; Chen C; Melchor-Khan L; Chang W; DePaoli AM; Ling L; Lieu HD
Lancet Gastroenterol Hepatol; 2022 Jul; 7(7):603-616. PubMed ID: 35325622
[TBL] [Abstract][Full Text] [Related]
11. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study.
Abdelmalek MF; Sanyal AJ; Nakajima A; Neuschwander-Tetri BA; Goodman ZD; Lawitz EJ; Harrison SA; Jacobson IM; Imajo K; Gunn N; Halegoua-DeMarzio D; Akahane T; Boone B; Yamaguchi M; Chatterjee A; Tirucherai GS; Shevell DE; Du S; Charles ED; Loomba R
Clin Gastroenterol Hepatol; 2024 Jan; 22(1):113-123.e9. PubMed ID: 37088458
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.
Cusi K; Alkhouri N; Harrison SA; Fouqueray P; Moller DE; Hallakou-Bozec S; Bolze S; Grouin JM; Jeannin Megnien S; Dubourg J; Ratziu V
Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):889-902. PubMed ID: 34560015
[TBL] [Abstract][Full Text] [Related]
13. Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis.
Verzijl CRC; Van De Peppel IP; Struik D; Jonker JW
Expert Opin Investig Drugs; 2020 Feb; 29(2):125-133. PubMed ID: 31899984
[No Abstract] [Full Text] [Related]
14. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.
Loomba R; Abdelmalek MF; Armstrong MJ; Jara M; Kjær MS; Krarup N; Lawitz E; Ratziu V; Sanyal AJ; Schattenberg JM; Newsome PN;
Lancet Gastroenterol Hepatol; 2023 Jun; 8(6):511-522. PubMed ID: 36934740
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial.
Noureddin M; Khan S; Portell F; Jorkasky D; Dennis J; Khan O; Johansson L; Johansson E; Sanyal AJ
Lancet Gastroenterol Hepatol; 2023 Dec; 8(12):1094-1105. PubMed ID: 37806314
[TBL] [Abstract][Full Text] [Related]
16. The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis.
Abdelmalek MF; Charles ED; Sanyal AJ; Harrison SA; Neuschwander-Tetri BA; Goodman Z; Ehman RA; Karsdal M; Nakajima A; Du S; Tirucherai GS; Klinger GH; Mora J; Yamaguchi M; Shevell DE; Loomba R
Contemp Clin Trials; 2021 May; 104():106335. PubMed ID: 33657443
[TBL] [Abstract][Full Text] [Related]
17. Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial.
Brown EA; Minnich A; Sanyal AJ; Loomba R; Du S; Schwarz J; Ehman RL; Karsdal M; Leeming DJ; Cizza G; Charles ED
JHEP Rep; 2023 Apr; 5(4):100661. PubMed ID: 36866389
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis.
Harrison SA; Neff G; Guy CD; Bashir MR; Paredes AH; Frias JP; Younes Z; Trotter JF; Gunn NT; Moussa SE; Kohli A; Nelson K; Gottwald M; Chang WCG; Yan AZ; DePaoli AM; Ling L; Lieu HD
Gastroenterology; 2021 Jan; 160(1):219-231.e1. PubMed ID: 32781086
[TBL] [Abstract][Full Text] [Related]
19. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
Neuschwander-Tetri BA; Loomba R; Sanyal AJ; Lavine JE; Van Natta ML; Abdelmalek MF; Chalasani N; Dasarathy S; Diehl AM; Hameed B; Kowdley KV; McCullough A; Terrault N; Clark JM; Tonascia J; Brunt EM; Kleiner DE; Doo E;
Lancet; 2015 Mar; 385(9972):956-65. PubMed ID: 25468160
[TBL] [Abstract][Full Text] [Related]
20. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
Younossi ZM; Ratziu V; Loomba R; Rinella M; Anstee QM; Goodman Z; Bedossa P; Geier A; Beckebaum S; Newsome PN; Sheridan D; Sheikh MY; Trotter J; Knapple W; Lawitz E; Abdelmalek MF; Kowdley KV; Montano-Loza AJ; Boursier J; Mathurin P; Bugianesi E; Mazzella G; Olveira A; Cortez-Pinto H; Graupera I; Orr D; Gluud LL; Dufour JF; Shapiro D; Campagna J; Zaru L; MacConell L; Shringarpure R; Harrison S; Sanyal AJ;
Lancet; 2019 Dec; 394(10215):2184-2196. PubMed ID: 31813633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]